<DOC>
	<DOC>NCT02170311</DOC>
	<brief_summary>The safety, tolerability, pharmacokinetics and pharmacodynamics of Z-213 will be investigated in patients with iron-deficiency anemia after administration of a single dose (100 mg, 500 mg, 800 mg or 1,000 mg iron).</brief_summary>
	<brief_title>Pharmacokinetics, Pharmacodynamics and Safety Study of Z-213 to Iron Deficiency Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia, Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<criteria>Patients with mild iron deficiency anemia Patients with anemia caused by conditions other than iron deficiency Patients with abnormal laboratory test values at screening for Creactive protein, Serum phosphorus, Aspartate aminotransferase, Alanine aminotransferase, Total bilirubin Patients with liver, kidney or circulatory system disease Patients with a history or present illness that is a malignant tumor or autoimmune disease Patients who underwent intravenous administration of an iron preparation, administration of an erythropoiesis stimulation agent or blood transfusion within 8 weeks before the screening Patients who underwent oral administration of an iron preparation (including an overthecounter drug or supplement) within 4 weeks before the screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Z-213, Ferric carboxymaltose, Iron, Iron-deficiency-anemia</keyword>
</DOC>